Danaher Corporation (NYSE:DHR) stock has experienced a notable downturn, reaching a 52-week low of $225.36. With a market capitalization of $163 billion, InvestingPro analysis indicates the stock is currently trading above its Fair Value.

Barclays lowered the firm’s price target on Danaher (DHR) to $240 from $275 and keeps an Equal Weight rating on the shares. The company

Danaher's Q4 earnings missed expectations due to a decline in its diagnostics segment, despite stronger sales in biotechnology and life sciences.

Danaher (DHR) stock trades ~5% lower as the company, with its Q4 2024 results, projects a sales contraction in the current quarter. Read more here.

In a report released today, Brandon Couillard from Wells Fargo maintained a Hold rating on Danaher (DHR – Research Report), with a price target

U.S. stocks slipped after the Federal Reserve held its main interest rate steady and broke a run of cuts that began in September

U.S. stocks are edging lower after the Federal Reserve opted not to cut interest rates for the first time since it began trying to help the economy in September. The

Wall Street drifts as investors await the Federal Reserve's interest rate decision and key earnings reports from Big Tech giants like Microsoft, Meta, and Tesla. AI developments and market reactions add uncertainty.

This positive outcome has rippled through the industry, with Danaher and Thermo Fisher anticipating their own earnings reports later this week. Analysts have weighed in on Sartorius's results, attributing the impressive fourth quarter to high demand for consumables,

In Asia, where many markets were closed for holidays, Japan’s Nikkei 225 rose 1%. AP Writers Matt Ott and Zimo Zhong contributed.

U.S. stocks slipped after the Federal Reserve held its main interest rate steady and broke a run of cuts that began in September. The S&P 500 fell 0.5% Wednesday. The